Successful Management of Steroid-Resistant cutaneous Acute Graft-versus-Host Disease, Toxic Epidermal Necrolysis-Like, with Ruxolitinib

Main Article Content

Fahir Ozturk
a:1:{s:5:"en_US";s:54:"Ankara Bilkent City Hospital Department of Hematology ";}

Mehmet Sezgin Pepeler
Ankara Bilkent City Hospital Department of Hematology

Esra Ucaryilmaz Ozhamam
Ankara Bilkent City Hospital Department of Pathology

Gulten Korkmaz

Keywords

Abstract

A case of Acute graft-versus-host disease (aGVHD)  with severe cutaneous manifestations resembling Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) is presented.

Downloads

Download data is not yet available.


Abstract 194
PDF Downloads 193
HTML Downloads 11

Article Sidebar

PDF HTML
Published
Feb 27, 2025
DOI https://doi.org/10.4084/MJHID.2025.020

Article Details

How to Cite

Ozturk, F. (2025) “Successful Management of Steroid-Resistant cutaneous Acute Graft-versus-Host Disease, Toxic Epidermal Necrolysis-Like, with Ruxolitinib”, Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025020. doi: 10.4084/MJHID.2025.020.
Issue
Vol. 17 No. 1 (2025): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Section
Letters to the Editor
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.